Skip to content

13F-HR filed by Darwin Global Management, Ltd.

Darwin Global Management, Ltd. filed this 13F-HR for the quarter ended 2024-03-31, filed 2024-05-15, with 12 holding rows worth $751,167,507.

Accession
0001892688-24-000066
Filed
2024-05-15
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2024

A holdings report, 12 entries on the cover page, a total value of $751,167,507 stated on the cover page (in dollars after the unit check, H1), rows summing to $751,167,507 with VALUE read as dollars as filed, 13F file number 028-21006. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
VAXCYTE INC COM92243G108Stock2,750,804$187,907,421dollars as filed
NUVALENT INC COM670703107Stock1,436,964$107,901,627dollars as filed
KEROS THERAPEUTICS INC COM492327101Stock1,435,950$95,059,890dollars as filed
BIOHAVEN LTDG1110E107COM1,476,974$80,775,708dollars as filed
ALPINE IMMUNE SCIENCES INC02083G100COM1,982,016$78,567,114dollars as filed
BEAM THERAPEUTICS INC07373V105COM2,119,598$70,031,518dollars as filed
APOGEE THERAPEUTICS INC COM03770N101Stock832,198$55,299,557dollars as filed
XENCOR INC98401F105COMMON STOCK1,109,650$24,556,555dollars as filed
SPYRE THERAPEUTICS INC00773J202COM NEW473,200$17,948,476dollars as filed
ELEVATION ONCOLOGY INC COM28623U101Stock2,332,928$11,967,921dollars as filed
Tourmaline Bio Inc89157D105Common Stock465,000$10,648,500dollars as filed
Merck & Co.,Inc.58933Y105COM79,600$10,503,220dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001892688-24-000066this filing2024-05-15acceptance time not in the bulk data set